UOC
EWTX icon

UBS O'Connor’s Edgewise Therapeutics EWTX Stock Holding History

UBS O'Connor’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-55,292
Closed -$725K – 341
2025
Q2 		$725K Buy
55,292
+15,278
+38% +$220K 0.02% 250
2025
Q1 		$880K Buy
+40,014
New +$1.05M 0.02% 199
2024
Q4 		– Sell
-20,000
Closed -$637K – 479
2024
Q3 		$534K Sell
20,000
-65,008
-76% -$1.29M 0.01% 339
2024
Q2 		$1.53M Buy
85,008
+9,911
+13% +$173K 0.04% 234
2024
Q1 		$1.37M Sell
75,097
-39,588
-35% -$629K 0.04% 242
2023
Q4 		$1.25M Sell
114,685
-25,173
-18% -$177K 0.04% 244
2023
Q3 		$801K Hold
139,858
– – 0.01% 355
2023
Q2 		$1.08M Buy
139,858
+6,890
+5% +$58.1K 0.02% 374
2023
Q1 		$887K Buy
+132,968
New +$1.23M 0.02% 425
2022
Q4 		– Sell
-110,750
Closed -$1.09M – 116
2022
Q3 		$1.09M Sell
110,750
-14,250
-11% -$144K 0.01% 738
2022
Q2 		$995K Buy
+125,000
New +$945K 0.01% 765

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

UBS O'Connor's EWTX Position: Q3 2025 in Review

UBS O'Connor sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 55,292 shares — an estimated $725K sold.

UBS O'Connor first reported a position in EWTX in Q2 2022 and held it in 11 quarters. The position peaked at $1.53M in Q2 2024. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • UBS O'Connor reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 55,292 Edgewise Therapeutics shares in Q3 2025, an estimated $725K.
  • UBS O'Connor first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 11 quarters.
  • UBS O'Connor's Edgewise Therapeutics position peaked at $1.53M in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.